Advertisement
Advertisement
TAK
Takeda Pharmaceutical Company Limited - ADR
18.29
USDSponsored
+0.25
+1.36%
Mar 25, 16:00 UTC -4
Closed
After-Market
18.40
+0.11
+0.62%
TAK Earnings Reports
Positive Surprise Ratio
TAK beat 27 of 39 last estimates.
69%
Next Report
Date of Next Report
May 13, 2026
Estimate for Q4 26 (Revenue/ EPS)
$1.13T
/-$23.99
Implied change from Q3 26 (Revenue/ EPS)
-5.02%
/-136.55%
Implied change from Q4 25 (Revenue/ EPS)
+7.45%
/-63.28%
Takeda Pharmaceutical Company Limited - ADR earnings per share and revenue
On Jan 30, 2026, TAK reported earnings of 65.64 USD per share (EPS) for Q3 26, beating the estimate of 34.44 USD, resulting in a 90.61% surprise. Revenue reached 1.19 trillion, compared to an expected 1.19 trillion, with a 0.21% difference. The market reacted with a +0.35% price change (close before vs. close after earnings).
Looking ahead to Q4 26, 5 analysts forecast an EPS of -23.99 USD, with revenue projected to reach 1.13 trillion USD, implying an decrease of -136.55% EPS, and decrease of -5.02% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Theravance Biopharma, Inc.
Report Date
Mar 19, 2026 For Q4 25
Estimate
$1.24
Actual
$0.21
Surprise
-83.12%
Context Therapeutics Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.10
Actual
-$0.14
Surprise
-29.39%
Avalo Therapeutics, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$1.49
Actual
-$1.12
Surprise
+24.33%
Surrozen, Inc. Common
Report Date
Mar 30, 2026 For Q4 25
Estimate
-$1.21
Actual
-Surprise
-
Achieve Life Sciences, Inc.
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.12%
Pyxis Oncology, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
-$0.34
Actual
-$0.28
Surprise
+15.55%
Acrivon Therapeutics, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.47
Actual
-$0.52
Surprise
-9.34%
Fractyl Health, Inc. Common Stock
Report Date
Mar 24, 2026 For Q4 25
Estimate
-$0.18
Actual
$0.15
Surprise
+181.70%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
Mar 23, 2026 For Q4 25
Estimate
$0.00
Actual
-$0.01
Surprise
-361.54%
electroCore, Inc. Common Stock
Report Date
Mar 19, 2026 For Q4 25
Estimate
-$0.41
Actual
-$0.34
Surprise
+18.15%
FAQ
What were Takeda Pharmaceutical Company Limited - ADR's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Takeda Pharmaceutical Company Limited - ADR reported EPS of $65.64, beating estimates by 90.61%, and revenue of $1.19T, 0.21% above expectations.
How did the market react to Takeda Pharmaceutical Company Limited - ADR's Q3 2026 earnings?
The stock price moved up 0.35%, changed from $17.17 before the earnings release to $17.23 the day after.
When is Takeda Pharmaceutical Company Limited - ADR expected to report next?
The next earning report is scheduled for May 13, 2026.
What are the forecasts for Takeda Pharmaceutical Company Limited - ADR's next earnings report?
Based on 5
analysts, Takeda Pharmaceutical Company Limited - ADR is expected to report EPS of -$23.99 and revenue of $1.13T for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement